Moreover, hypoxia has been observed to induce TIME inhibition in AML, and to affect the malignant progression of AML through the activation of the mTOR signaling pathway and overexpression of PSMD11 and PSMD14. Anti-tumor drug analysis revealed that patients in the high-risk group were more sensitive to mTOR inhibitors and proteasome inhibitors. This evidence concerns the gene MTOR and acute myeloid leukemia.